Evidence map›Paper›PMID 25816224›Full record

Trial reportPLoS pathogens2015

Early virological and immunological events in asymptomatic Epstein-Barr virus infection in African children.

Shamanthi Jayasooriya, Thushan I de Silva, Jainaba Njie-jobe, Chilel Sanyang, Alison M Leese, Andrew I Bell, Karen A McAulay, Peng Yanchun, Heather M Long, Tao Dong and 5 more

Open access · goldAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in PLoS pathogens, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
5.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 120 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Epstein-Barr virus BALF0/1 subverts the Caveolin and ERAD pathways to target B cell receptor complexes for degradation.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 3 countries.

Shamanthi JayasooriyaMedical Research Council Laboratories, Fajara, The Gambia; School of Cancer Sciences, University of Birmingham, Edgbaston, United Kingdom.
Thushan I de SilvaMedical Research Council Laboratories, Fajara, The Gambia; Department of Infection and Immunity, The University of Sheffield Medical School, Sheffield, United Kingdom; The Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, United Kingdom.
Jainaba Njie-jobeMedical Research Council Laboratories, Fajara, The Gambia.
Chilel SanyangMedical Research Council Laboratories, Fajara, The Gambia.
Alison M LeeseSchool of Cancer Sciences, University of Birmingham, Edgbaston, United Kingdom.
Andrew I BellSchool of Cancer Sciences, University of Birmingham, Edgbaston, United Kingdom.
Karen A McAulayMRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom.
Peng YanchunThe Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, United Kingdom.
Heather M LongSchool of Cancer Sciences, University of Birmingham, Edgbaston, United Kingdom.
Tao DongThe Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, United Kingdom.
Hilton C WhittleMedical Research Council Laboratories, Fajara, The Gambia; London School of Hygiene and Tropical Medicine, London, United Kingdom.
Alan B RickinsonSchool of Cancer Sciences, University of Birmingham, Edgbaston, United Kingdom.
Sarah L Rowland-JonesNuffied Department of Medicine, NDM Research Building, University of Oxford, Old Road Campus, Headington, United Kingdom.
Andrew D HislopSchool of Cancer Sciences, University of Birmingham, Edgbaston, United Kingdom.
Katie L FlanaganMedical Research Council Laboratories, Fajara, The Gambia; Department of Immunology, Monash University, Commercial Road, Prahran, Melbourne, Victoria, Australia.
University of Birmingham · GBMRC Unit the Gambia · GMJohn Radcliffe Hospital · GBUniversity of Oxford · GBLondon School of Hygiene & Tropical Medicine · GBMonash University · AUMRC University of Glasgow Centre for Virus Research · GB

Funding

Cancer Research UK 15032Medical Research Council G0600520Medical Research Council G0801751Medical Research Council G1001046Medical Research Council G9901294Medical Research Council MR/L018942/1Worldwide Cancer Research 13-0102
6 · The paper itself

Abstract

Epstein-Barr virus (EBV) infection often occurs in early childhood and is asymptomatic. However, if delayed until adolescence, primary infection may manifest as acute infectious mononucleosis (AIM), a febrile illness characterised by global CD8+ T-cell lymphocytosis, much of it reflecting a huge expansion of activated EBV-specific CD8+ T-cells. While the events of AIM have been intensely studied, little is known about how these relate to asymptomatic primary infection. Here Gambian children (14-18 months old, an age at which many acquire the virus) were followed for the ensuing six months, monitoring circulating EBV loads, antibody status against virus capsid antigen (VCA) and both total and virus-specific CD8+ T-cell numbers. Many children were IgG anti-VCA-positive and, though no longer IgM-positive, still retained high virus loads comparable to AIM patients and had detectable EBV-specific T-cells, some still expressing activation markers. Virus loads and the frequency/activation status of specific T-cells decreased over time, consistent with resolution of a relatively recent primary infection. Six children with similarly high EBV loads were IgM anti-VCA-positive, indicating very recent infection. In three of these donors with HLA types allowing MHC-tetramer analysis, highly activated EBV-specific T-cells were detectable in the blood with one individual epitope response reaching 15% of all CD8+ T-cells. That response was culled and the cells lost activation markers over time, just as seen in AIM. However, unlike AIM, these events occurred without marked expansion of total CD8+ numbers. Thus asymptomatic EBV infection in children elicits a virus-specific CD8+ T-cell response that can control the infection without over-expansion; conversely, in AIM it appears the CD8 over-expansion, rather than virus load per se, is the cause of disease symptoms.

Indexed as

Antibodies, ViralCD8-Positive T-LymphocytesEpstein-Barr Virus InfectionsFemaleGambiaHerpesvirus 4, HumanHumansImmunoglobulin MInfantLymphocyte CountMaleAntibodies, ViralImmunoglobulin M

Identifiers

PMID25816224
PMCPMC4376400
OpenAlexW2112017011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.